合成,表征和酶抑制评估西塔格利普衍生物及其金属复合物
Javed Ahmed1, Mohsin Abbas Khan1,2, Saharish Khaliq1
1Department of Pharmaceutical Chemistry, The Islamia University of Bahawalpur Pakistan, Bahawalpur, Pakistan.
Future medicinal chemistry
|January 2, 2025
概括
新型西塔利普丁衍生物及其金属复合物通过抑制关键酶显示出作为抗糖尿病药物的显著潜力. 需要进一步的研究来解决治疗开发的生物可用性挑战.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 协调化学 协调化学
背景情况:
- 2型糖尿病 (T2DM) 管理需要强效的口服抗糖尿病药物,副作用最小.
- 西塔格利平是用于T2DM治疗的广泛使用的迪佩代酶-4 (DPP-4) 抑制剂.
- 开发新的衍生品和金属复合物可以提供替代治疗策略.
研究的目的:
- 合成和表征新型西塔利普丁衍生物及其铜 (II) 和 (II) 金属复合物.
- 通过酶抑制测定来评估这些化合物的抗糖尿病潜力.
- 探索结构-活性关系和新T2DM治疗方法的潜力.
主要方法:
- 使用模板反应合成基于西塔利普丁的衍生物及其金属复合物.
- 通过元素分析,FTIR,UV-Vis,1H NMR和13C NMR光谱学进行表征.
- 在体外酶抑制试验 (α-氨基酶和α-葡萄糖酶) 和分子模拟研究.
主要成果:
- 几种衍生药物 (SD7,SD4,SD3,SD5,SD9) 呈现出与标准抑制剂相当的酶抑制.
- 金属复杂物已成功合成和表征.
- 发现金属复合物的吸收问题可能会影响生物可用性.
结论:
- 合成的西塔利普丁衍生物及其金属复合物具有显著的抗糖尿病潜力.
- 这些化合物显示出作为未来抗糖尿病药物开发的分子的前景.
- 需要进一步优化以克服生物可用性限制.
相关概念视频
01:23Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
00:43Complexometric Titration: Ligands
897
Different monodentate and polydentate ligands are used as complexing agents in complexometric titration reactions. The formation of complexes by mono- and bidentate ligands involves two or more intermediate steps, limiting their use as complexing agents. In comparison, polydentate ligands can form complexes with metal ions in a single-step process, facilitating sharper end points. This means polydentate ligands, such as amino carboxylic acid derivatives, are most commonly employed in...
897
01:06Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
01:24Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165
01:28Structure-Activity Relationships and Drug Design
494
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
494